Abstract
In the United Kingdom (UK), the National Health Service (NHS) provides population-based screening programmes for breast, bowel, and cervical cancer. These programmes were temporarily paused in March 2020, due to the COVID-19 pandemic, resulting in large numbers of the eligible population having their invitations delayed. This disruption may have had a disproportionate impact on underserved populations for whom there was a lower uptake prior to the pandemic. Some people may also be less willing to attend screening after the pandemic. Interventions and campaigns designed to encourage people to take part in cancer screening may need to be adapted after the pandemic, in particular those targeting underserved populations.
This rapid review aimed to identify the barriers and facilitators to breast, bowel, and cervical screening uptake in underserved populations (e.g. clinically vulnerable, shielding, multi-morbidities, ethnic minorities, social deprivation, gender, age) during and since the onset of the pandemic, using evidence from the UK and other countries with similar cancer screening programmes (such as Australia and Netherlands), and to compare with the pre-pandemic literature. The pre-pandemic literature was identified using a supplementary scoping search for published systematic reviews.
Three primary studies (two published and one ongoing trial) conducted during the pandemic were identified. Five systematic reviews of pre-pandemic evidence were also included. Two qualitative studies conducted during the pandemic were appraised as high quality but both included sample populations with limited representation.
No primary studies specifically exploring the impact of the pandemic on barriers and facilitators to screening uptake among underserved groups were identified. The findings did not show marked differences in the barriers and facilitators for screening uptake before and during the COVID-19 pandemic in underserved populations. However, it is unclear whether this is because these genuinely remain unchanged or reflects the lack of available evidence. The findings may only be transferable to the population groups studied.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Public Health Wales Evidence Service was funded for this work by the Wales Covid-19 Evidence Centre, itself funded by Health & Care Research Wales on behalf of Welsh Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding statement: The Public Health Wales Evidence Service was funded for this work by the Wales Covid-19 Evidence Centre, itself funded by Health & Care Research Wales on behalf of Welsh Government.
Wales COVID-19 Evidence Centre (WCEC) Rapid Review
Barriers and facilitators to cancer screening uptake (breast, cervical and bowel) in underserved populations
Report number – RR00035, June 2022
Rapid Review Details
Review conducted by:
Public Health Wales
Review Team:
Hannah Shaw
Chukwudi Okolie
Alesha Wale
Jordan Everitt
Review submitted to the WCEC on:
14th June 2022
Stakeholder consultation meeting:
28th June 2022
Rapid Review report issued by the WCEC in:
[July 2022]
WCEC Team:
Adrian Edwards, Alison Cooper, Ruth Lewis, Micaela Gal and Jane Greenwell involved in drafting Topline Summary, review and editing
This review should be cited as:
RR00035. Wales COVID-19 Evidence Centre. A rapid review of the barriers and facilitators to cancer screening uptake (breast, cervical and bowel) in underserved populations. July 2022
This report can be downloaded here: https://healthandcareresearchwales.org/wales-covid-19-evidence-centre-report-library
Disclaimer: The views expressed in this publication are those of the authors, not necessarily Health and Care Research Wales. The WCEC and authors of this work declare that they have no conflict of interest.
Barriers and facilitators to cancer screening uptake (breast, cervical and bowel) in underserved populations
Report number – RR00035, June 2022
TOPLINE SUMMARY
What is a Rapid Review?
Our rapid reviews use a variation of the systematic review approach, abbreviating or omitting some components to generate the evidence to inform stakeholders promptly whilst maintaining attention to bias. They follow the methodological recommendations and minimum standards for conducting and reporting rapid reviews, including a structured protocol, systematic search, screening, data extraction, critical appraisal, and evidence synthesis to answer a specific question and identify key research gaps. They take 1- 2 months, depending on the breadth and complexity of the research topic/ question(s), extent of the evidence base, and type of analysis required for synthesis.
Who is this summary for?
Screening Division of Public Health Wales
Background / Aim of Rapid Review
In the United Kingdom (UK), the National Health Service (NHS) provides population-based screening programmes for breast, bowel, and cervical cancer. These programmes were temporarily paused in March 2020, due to the COVID-19 pandemic, resulting in large numbers of the eligible population having their invitations delayed. This disruption may have had a disproportionate impact on underserved populations for whom there was a lower uptake prior to the pandemic. Some people may also be less willing to attend screening after the pandemic. Interventions and campaigns designed to encourage people to take part in cancer screening may need to be adapted after the pandemic, in particular those targeting underserved populations. This rapid review aimed to identify the barriers and facilitators to breast, bowel, and cervical screening uptake in underserved populations (e.g. clinically vulnerable, shielding, multi-morbidities, ethnic minorities, social deprivation, gender, age) during and since the onset of the pandemic, using evidence from the UK and other countries with similar cancer screening programmes (such as Australia and Netherlands), and to compare with the pre-pandemic literature. The pre-pandemic literature was identified using a supplementary scoping search for published systematic reviews.
Key Findings
Three primary studies (two published and one ongoing trial) conducted during the pandemic were identified. Five systematic reviews of pre-pandemic evidence were also included.
Extent of the evidence base
One qualitative study assessed the perceived barriers for attending breast cancer screening among Irish Traveller women in the Republic of Ireland.
One qualitative study explored barriers and facilitators to breast, colorectal and cervical screening uptake among Muslim women in Scotland.
One UK ongoing randomised controlled trial (RCT) of a behaviour change intervention to increase cervical cancer uptake in deprived and non-deprived populations (implemented during the pandemic) includes data collection on pre-specified barriers.
Five systematic reviews reporting pre-pandemic evidence on barriers and facilitators to breast, bowel, and cervical screening uptake in various underserved populations were identified. The reviews reported barriers and facilitators among Black, Asian and minority ethnic (BAME) groups, low-uptake sociodemographic groups, people with mental illness or learning disabilities, people with physical disabilities, Lesbian, Gay, Bisexual and Trans (LGBT) people and underserved women.
Recency of the evidence base
The data for the qualitative studies were collected in early 2021 (March) and 2022
Evidence of effectiveness
Despite being conducted during the COVID-19 pandemic, neither qualitative study focused specifically on the impact of the pandemic on perceptions towards cancer screening among underserved groups.
Barriers identified during the pandemic included: fear of negative outcome; fear of procedure; embarrassment and health care professional; lack of family and community support; lack of education and awareness; literacy; social stigma surrounding cancers; cultural and language barriers; appointment suitability.
Pre-pandemic barriers included: fear and anxiety; shame and embarrassment; lack of knowledge and awareness; perceived stigma associated with cancer; language and communication barriers; lack of support from family and community; religious and cultural beliefs; logistical barriers; gender of practitioner; medical mistrust; threat to masculinity; discrimination and racism; misgendering; negative past experiences.
Facilitators identified during the pandemic included: trust; offering language support; use of personal testimonies/stories of cancer screening and survival during focus group meetings.
Pre-pandemic facilitators included: positive past experiences; encouragement from healthcare professionals; supportive family members and communities; transport provision; offering language support; friendly and approachable healthcare staff; practitioner endorsement; educational support.
Best quality evidence
The two qualitative studies conducted during the pandemic were appraised as high quality but both included sample populations with limited representation.
Policy Implications
No primary studies specifically exploring the impact of the pandemic on barriers and facilitators to screening uptake among underserved groups were identified.
The findings did not show marked differences in the barriers and facilitators for screening uptake before and during the COVID-19 pandemic in underserved populations. However, it is unclear whether this is because these genuinely remain unchanged or reflects the lack of available evidence.
The findings may only be transferable to the population groups studied.
Strength of Evidence
The evidence is limited to two qualitative studies conducted during the pandemic. Both studies were good quality but only had limited information and partial relevance to address the review question.
Data Availability
All data produced in the present study are available upon reasonable request to the authors